Mark Fleming MD Of US Oncology Research Discusses TITAN Trial: Many Options Including Chemo, Abiraterone, Enzalutamide, & Apalutamide All Showing…
Browsing: Prostate
Daniel George MD @daniel_j_george Of Duke University Cancer Institute Discusses Disparity Associated With Our Patient Population: African Americans Make Up…
Heather Cheng MD Of Seattle Cancer Care Alliance Discusses Molecular Tumor Boards In Clinical Practice: Increasingly Needed, GENTleMEN Study Offers…
Heather Cheng MD Of Seattle Cancer Care Alliance Discusses How To Help Men With BRCA1 & BRCA2 Mutations: Now Have…
Heather Cheng MD Of Seattle Cancer Care Alliance Discusses GENTleMEN Study: www.Gentlemen.org, Get A Saliva Kit Mailed To You &…
Kim Nguyen Chi MD Of The University Of British Colombia Discusses TITAN Study & Docetaxel: There Is Some Support To…
Kim Nguyen Chi MD Of The University Of British Colombia Discusses TITAN Study: Phase III Double-Blind, Randomized Study Of Apalutamide…
Dr. Celestia Higano, MD from the University of Washington discusses the PEACE III Trial Decreased Fracture Rate by Mandating Bone-protecting…
Dr. Celestia Higano, MD of the University of Washington discusses the Alliance A031201 a phase III trial of enzalutamide (ENZ)…
Neeraj Agarwal MD @neerajaiims Of Huntsman Cancer Institute Discusses Strength Of Talazoparib: Traps PARP On The DNA & Inhibits It…
Neeraj Agarwal MD @neerajaiims Of Huntsman Cancer Institute Discusses TALAPRO-2 Trial Patient Screening: No Need To Be Screened For Specific…
Dr. Celestia Higano, MD of the University of Washington discusses the Titan Trial Apalutamide vs Placebo During Androgen-Deprivation Therapy for…
Neeraj Agarwal MD @neerajaiims Of Huntsman Cancer Institute Discusses TALAPRO-2 Trial: Phase 3 Study Of Talazoparib (TALA) With Enzalutamide (ENZA)…
Neeraj Agarwal MD @neerajaiims Of Huntsman Cancer Institute Discusses Talazoparib + Enzalutamide Combo: Combination Is Safe & Works By Attacking…
Dr. Celestia Higano, MD of the University of Washington discusses the 10 year follow up of the Getug 16 Trial…
Dr. Ash Tewari discusses the concept of race vs. genetics in Health Disparity research and treatment
Evan Yu, MD, Professor, Department of Medicine, Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Institute, Discusses Results…
Evan Yu, MD, Professor, Department of Medicine, Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Institute, Discusses When…
Evan Yu, MD, Professor, Department of Medicine, Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Institute, Discusses Combining…
Evan Yu, MD, Professor, Department of Medicine, Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Institute, Discusses Combination…
Sumit K. Subudhi, MD, PhD, Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas…
Sumit K. Subudhi, MD, PhD, Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas…
Bridget F. Koontz, MD, Associate Professor of Radiation Oncology, Duke University School of Medicine, Discusses Moderate Hypofractionation & Ultra-Hypofractionation In…
Bridget F. Koontz, MD, Associate Professor of Radiation Oncology, Duke University School of Medicine, Discusses The Evolving Landscape Of Prostate…
Bridget F. Koontz, MD, Associate Professor of Radiation Oncology, Duke University School of Medicine, Discusses New Guidelines On Hypofractionated EBRT…
Tomasz Beer, MD, Professor of Medicine, Division of Hematology/Medical Oncology, Oregon Health Sciences University, Discusses Recent Data Utilizing LuPSMA In…
Tomasz Beer, MD, Professor of Medicine, Division of Hematology/Medical Oncology, Oregon Health Sciences University, Discusses The ARAMIS Study In nmCRPC…
William Oh, MD, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, Discusses The Evolving Treatment Landscape For Patients…
William Oh, MD, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, Discusses How PSA Is Valuable As A…
William Oh, MD, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, Discusses Data On Racial Differences In Response…
William Oh, MD, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, Discusses Recent Data Examining LuPSMA In Men…
Mark T. Fleming, MD, Medical Oncology, Medical Director, Genitourinary Program, US Oncology, Virginia Oncology Associates, Discusses The Implications Of The…
Mark T. Fleming, MD, Medical Oncology, Medical Director, Genitourinary Program, US Oncology, Virginia Oncology Associates, Discusses The LATITUDE Study In…
Mark T. Fleming, MD, Medical Oncology, Medical Director, Genitourinary Program, US Oncology, Virginia Oncology Associates, Discusses Aramis Study In Prostate…
Mark T. Fleming, MD, Medical Oncology, Medical Director, Genitourinary Program, US Oncology, Virginia Oncology Associates, Discusses The ARCHES Trial In…
Nicholas Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, Discusses The Evolution Of ADT In Prostate Cancer.…
Nicholas Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, Discusses Impression Of KEYNOTE 365 In mCRPC. At…
Nicholas Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, Discusses Impression Of KEYNOTE 365 In mCRPC. At…
Nicholas Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, Discusses Combining Checkpoint Inhibitors In mCRPC. At The…
Andrew Armstrong, MD Professor of Medicine, Duke Cancer Institute, Center for Prostate and Urologic Cancers, Discusses Phase 2 STREAM Study…
Andrew Armstrong, MD Professor of Medicine, Duke Cancer Institute, Center for Prostate and Urologic Cancers, Discusses Opinion On Androgen Receptor…
Andrew Armstrong, MD Professor of Medicine, Duke Cancer Institute, Center for Prostate and Urologic Cancers, Discusses Overview Of The ARCHES…
Dr. Ashutosh Tewari discusses the nature of genetic difference and aggressiveness among African-Ameican men
Dr. Nihal Mohamed discusses research on active surveillance among high risk populations, particularly African-American
Dr. Susan Slovin discusses the newly discovered Mo stage of prostate cancer
Dr. William Oh discusses the role of PARP inhibitors in treating prostate cancer
Dr. William Oh discusses the potential for immunotherapy in treating prostate cancer
Dr. Susan Slovin discusses how the evolution of therapeutic treatment is occurring in advanced stage prostate cancer
The concept of Precision Therapy in Prostate Cancer treatment will need to rely more heavily on genetic testing
Scott Tagawa, M.D., of Weill Cornell Medicine discusses PSMA-617 Study. At ESMO Oncology Conference – Munich, Germany On October 19,…